Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
MV Cannizzaro, C Franceschini… - … : Targets and Therapy, 2017 - Taylor & Francis
The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV
patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis …
patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis …
[HTML][HTML] Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM …
J Sanz-Bueno, F Vanaclocha, I García-Doval… - Actas Dermo …, 2015 - Elsevier
Introduction and objectives A 5% risk of reactivation of hepatitis B virus (HBV) infection has
been reported in patients with diseases other than psoriasis treated with tumor necrosis …
been reported in patients with diseases other than psoriasis treated with tumor necrosis …
Use of anti‐tumor necrosis factor‐α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan
YT CHO, CH CHEN, HY CHIU… - The Journal of …, 2012 - Wiley Online Library
The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …
Risk for hepatitis b virus reactivation in patients with psoriasis treated with biological agents: A systematic review and meta-analysis
X Wang, M Zhang, Y Chen, Y Liu, Y Yu, X Huang… - Dermatology and …, 2022 - Springer
Introduction Notwithstanding their numerous advantages, biological treatments have many
limitations when treating patients with psoriasis (PsO) and hepatitis B (HB). Clinicians need …
limitations when treating patients with psoriasis (PsO) and hepatitis B (HB). Clinicians need …
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature
Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
HY Chiu, YM Chiu, NFC Liao, CC Chi, TF Tsai… - Journal of the American …, 2021 - Elsevier
Background The increasing use of biologics is accompanied by a risk of hepatitis B (HBV)
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …
Managing psoriasis in patients with HBV or HCV infection: practical considerations
S Piaserico, F Messina, FP Russo - American Journal of Clinical …, 2019 - Springer
Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report
A Raducan, S Bucur, C Caruntu… - Experimental and …, 2019 - spandidos-publications.com
Systemic therapy in patients with concurrent psoriasis and chronic hepatitis B is a
challenging task for both dermatologists and gastroenterologists since there is a high risk for …
challenging task for both dermatologists and gastroenterologists since there is a high risk for …
Safety of anti‐tumour necrosis factor‐α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of …
C Fotiadou, E Lazaridou… - Journal of the European …, 2011 - Wiley Online Library
Background Issues concerning the potential risks of reactivating chronic hepatitis B virus
arise when the use of anti‐Tumour Necrosis Factor‐α (TNFα) agents is imperative in patients …
arise when the use of anti‐Tumour Necrosis Factor‐α (TNFα) agents is imperative in patients …
[HTML][HTML] Management of psoriasis patients with hepatitis B or hepatitis C virus infection
C Bonifati, V Lora, D Graceffa… - World journal of …, 2016 - ncbi.nlm.nih.gov
The systemic therapies available for the management of Psoriasis (PsO) patients who
cannot be treated with more conservative options, such as topical agents and/or …
cannot be treated with more conservative options, such as topical agents and/or …